Regional variations in adverse event reporting rates and ACR responses in placebo/standard-of-care arms of rheumatoid arthritis trials
Open Access
- 1 October 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 59 (10), 3023-3031
- https://doi.org/10.1093/rheumatology/keaa043
Abstract
Objective. Clinical trials are increasingly globalized, and adverse event (AE) rates and treatment responses may differ by geographical region. This study assessed regional differences in AE reporting rates and ACR response rates (ACR20/50) in patients with RA who received placebo/standard-of-care treatment in clinical trials. Methods. Patients from the placebo arms of 7 RA trials in the TransCelerate Biopharma Inc database were grouped into 5 geographical regions (Asia, Latin America, Russian Federation and Eastern Europe [RFEE], USA, and Western Europe). Differences in demographics, AE reporting rates and ACR response were evaluated using descriptive statistics and omnibus tests for significance; pairwise comparisons were made between regions, with false discovery rate correction for multiple comparisons. Results. Among 970 patients included, week 12 AE rates were significantly lower in the RFEE than in Asia, Latin America and the USA (22% vs 51%, 49% and 53%, respectively; P < 0.05 after false discovery rate correction). Similar differences in AE rates across geographical regions were seen at week 52. Among 747 patients with ACR data, the lowest response rates were observed in the USA (ACR20, 22%) and RFEE (ACR50, 3%); the highest response rates were seen in Western Europe (ACR20, 43%) and Latin America (ACR50, 15%). Only the differences in ACR50 response between the RFEE and Latin America remained significant after false discovery rate correction. Conclusion. These placebo/standard-of-care arm data revealed significant regional differences in AE reporting rates and ACR50 response rates. Regional distribution of patients should be considered when conducting RA clinical trials, particularly during recruitment.Funding Information
- Genentech, Inc.
This publication has 28 references indexed in Scilit:
- Re-inventing clinical trials through TransCelerateNature Reviews Drug Discovery, 2014
- Randomized Controlled Trials of Rheumatoid Arthritis Registered at ClinicalTrials.gov: What Gets Published and WhenArthritis & Rheumatology, 2014
- Rheumatoid arthritis in the developing world: stepping up to the challengeClinical Rheumatology, 2014
- Global migration of clinical trialsNature Reviews Drug Discovery, 2014
- Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?Annals Of The Rheumatic Diseases, 2013
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2013
- Suboptimal management of rheumatoid arthritis in the Middle East and Africa: could the EULAR recommendations be the start of a solution?Clinical Rheumatology, 2012
- Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled studyInternational Journal of Neuropsychopharmacology, 2011
- So Different, yet So Similar: Meta-Analysis and Policy Modeling of Willingness to Participate in Clinical Trials among Brazilians and IndiansPLOS ONE, 2010
- Ethical and Scientific Implications of the Globalization of Clinical ResearchThe New England Journal of Medicine, 2009